| Company
| InsiderPie Expert Score
| P/E ratio
| Gross margin
| EBIT margin
| ROA
| Net income per employee
|
| Deciphera Pharmaceuticals, Inc.
|
53
/ 100
| -12
| 96.0%
| -118.1%
| -45.2%
| -€456.81K
|
| PolyPeptide Group AG
|
50
/ 100
| -13
| 8.5%
| -4.6%
| -8.2%
| -€46.46K
|
| Dermapharm Holding SE
|
53
/ 100
| 18
| 65.7%
| 18.5%
| 5.0%
| €29.70K
|
| Biofrontera AG
|
50
/ 100
| -17
| 80.6%
| 14.8%
| -1.2%
| -€4.05K
|
| Neurocrine Biosciences, Inc.
|
57
/ 100
| 29
| 98.4%
| 20.5%
| 10.0%
| €202.50K
|
| Supernus Pharmaceuticals, Inc.
|
54
/ 100
| -97
| 78.4%
| -5.6%
| -1.3%
| -€24.16K
|
| Ironwood Pharmaceuticals, Inc.
|
55
/ 100
| 4
| 99.7%
| 36.9%
| 7.4%
| €99.24K
|
| Lifecore Biomedical, Inc.
|
49
/ 100
| -7.7
| 31.6%
| -18.9%
| -13.8%
| -€52.79K
|
| AB Science S.A.
|
50
/ 100
| -4.8
| 51.7%
| -682.7%
| -68.7%
| -€364.55K
|
| Zoetis Inc.
|
65
/ 100
| 28
| 71.0%
| 37.6%
| 17.5%
| €163.60K
|
| Shield Therapeutics plc
|
50
/ 100
| -0.0057
| 40.3%
| -78.8%
| -72.7%
| -€825.90K
|
| Swedencare AB (publ)
|
50
/ 100
| 109
| 43.8%
| 6.4%
| 0.7%
| €10.15K
|
| Boiron SA
|
50
/ 100
| 9.3
| 73.3%
| 8.1%
| 7.7%
| €17.44K
|
| Aytu BioPharma, Inc.
|
50
/ 100
| -0.91
| 67.6%
| -13.2%
| -10.5%
| -€109.14K
|
| Apontis Pharma AG
|
56
/ 100
| -14
| 15.0%
| -10.5%
| -14.6%
| -€46.89K
|
| Eagle Pharmaceuticals, Inc.
|
50
/ 100
| 1.9
| 69.8%
| 9.2%
| 3.8%
| €98.93K
|
| Shionogi & Co., Ltd.
|
50
/ 100
| 12
| 85.5%
| 37.5%
| 11.6%
| €194.69K
|
| Dr. Reddy's Laboratories Limited
|
55
/ 100
| 20
| 57.7%
| 21.4%
| 10.9%
| €19.47K
|
| ECO Animal Health Group plc
|
52
/ 100
| 0.16
| 43.5%
| 4.6%
| 2.3%
| €13.87K
|
| Intra-Cellular Therapies, Inc.
|
51
/ 100
| -189
| 91.6%
| -17.1%
| -5.5%
| -€73.95K
|
| Allergy Therapeutics plc
|
50
/ 100
| -0.04
| 53.3%
| -64.2%
| -117.7%
| -€161.62K
|
| Evolus, Inc.
|
51
/ 100
| -11
| 65.9%
| -13.7%
| -26.7%
| -€134.07K
|
| Aspen Pharmacare Holdings Limited
|
50
/ 100
| 265
| 43.8%
| 11.4%
| 2.4%
| €19.76K
|
| SCYNEXIS, Inc.
|
48
/ 100
| -1.4
| 53.5%
| -1,181.1%
| -49.5%
| -€769.52K
|
| PLx Pharma Inc.
|
50
/ 100
| -0.17
| 4.5%
| -880.5%
| -45.6%
| -€806.11K
|
| Fagron NV
|
50
/ 100
| 9.8
| 33.9%
| 15.0%
| 14.6%
| €42.74K
|
| Almirall, S.A.
|
54
/ 100
| 110
| 78.1%
| 4.9%
| 0.9%
| €10.53K
|
| HUTCHMED (China) Limited
|
51
/ 100
| 6.7
| 8.9%
| -3.3%
| 26.3%
| €219.56K
|
| Elanco Animal Health Incorporated
|
52
/ 100
| 198
| 49.2%
| 5.2%
| 0.3%
| €3.41K
|
| Evotec SE
|
51
/ 100
| -8.5
| 10.8%
| -11.3%
| -9.0%
| -€33.36K
|
| Siegfried Holding AG
|
50
/ 100
| 16
| 25.8%
| 14.6%
| 14.4%
| €78.51K
|
| Mithra Pharmaceuticals SA
|
50
/ 100
| -0.062
| 38.7%
| -96.4%
| -81.4%
| -€863.41K
|
| Collegium Pharmaceutical, Inc.
|
50
/ 100
| 16
| 57.2%
| 20.9%
| 3.6%
| €139.42K
|
| Sumitomo Pharma Co., Ltd.
|
51
/ 100
| 3.5K
| 60.9%
| 12.6%
| 2.6%
| €20.44K
|
| Green Thumb Industries Inc.
|
51
/ 100
| 20
| 51.1%
| 15.2%
| 1.7%
| €7.58K
|
| MERCK Kommanditgesellschaft auf Aktien
|
54
/ 100
| 15
| 58.5%
| 18.0%
| 6.0%
| €48.51K
|
| Lantheus Holdings, Inc.
|
51
/ 100
| 33
| 62.2%
| 22.8%
| 7.4%
| €176.74K
|
| Ipsen S.A.
|
51
/ 100
| 6.5
| 82.5%
| 20.0%
| 16.5%
| €210.73K
|
| Mountain Valley MD Holdings Inc.
|
50
/ 100
| -0.95
| -26.5%
| -5,608.2%
| -272.4%
| €0.00
|
| Dynavax Technologies Corporation
|
55
/ 100
| -28
| 83.2%
| 3.2%
| -4.6%
| -€91.26K
|
| Vetoquinol SA
|
50
/ 100
| 8.1
| 44.1%
| 11.9%
| 14.8%
| €42.52K
|
| ANI Pharmaceuticals, Inc.
|
50
/ 100
| 37
| 55.6%
| 7.1%
| 2.6%
| €35.38K
|
| Viatris Inc.
|
52
/ 100
| -2.9
| 36.1%
| -18.4%
| -9.7%
| -€98.24K
|
| Takeda Pharmaceutical Company Limited
|
53
/ 100
| 211
| 60.3%
| 6.6%
| 0.2%
| €3.61K
|
| Tilray Brands, Inc.
|
42
/ 100
| -0.2
| 28.7%
| -235.1%
| -102.9%
| -€688.68K
|
| Athenex, Inc.
|
50
/ 100
| -0.023
| 23.0%
| -61.7%
| -50.4%
| -€325.74K
|
| CV Sciences, Inc.
|
50
/ 100
| -3.3
| 60.8%
| -9.4%
| -21.1%
| -€26.78K
|
| Hikma Pharmaceuticals PLC
|
54
/ 100
| 9.6
| 43.7%
| 15.6%
| 11.8%
| €58.65K
|
| Aerie Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 89.0%
| -10.9%
| -9.7%
| -€82.80K
|
| Trees Corporation
|
50
/ 100
| -0.69
| 42.6%
| -5.1%
| -20.0%
| -€38.87K
|
| PetIQ, Inc.
|
50
/ 100
| 70
| 24.6%
| 5.7%
| 1.5%
| €10.02K
|
| Sonoma Pharmaceuticals, Inc.
|
47
/ 100
| -1.5
| 37.7%
| -18.4%
| -25.1%
| -€296.29K
|
| Eisai Co., Ltd.
|
51
/ 100
| 24
| 78.3%
| 6.8%
| 3.4%
| €24.02K
|
| Alliance Pharma plc
|
50
/ 100
| -0.08
| 54.0%
| 19.3%
| -11.9%
| -€174.24K
|
| Organogenesis Holdings Inc.
|
47
/ 100
| -237
| 73.1%
| -1.8%
| -0.3%
| -€1.71K
|
| Esperion Therapeutics, Inc.
|
49
/ 100
| -2.5
| 56.2%
| -7.1%
| -26.9%
| -€274.25K
|
| Sandoz Group AG
|
49
/ 100
| 76
| 46.3%
| 11.7%
| 1.4%
| €12.00K
|
| Teva Pharmaceutical Industries Limited
|
50
/ 100
| 27
| 50.1%
| 10.9%
| 1.8%
| €16.39K
|
| Emergent BioSolutions Inc.
|
50
/ 100
| 4.8
| 49.9%
| 15.1%
| 5.2%
| €71.82K
|
| China Shineway Pharmaceutical Group Limited
|
50
/ 100
| 22
| 74.4%
| 20.6%
| 2.4%
| €67.10K
|
| Cosmos Health Inc.
|
50
/ 100
| -0.95
| 9.8%
| -26.7%
| -24.9%
| -€87.86K
|
| Biostar Pharmaceuticals, Inc.
|
50
/ 100
| 0.00028
| -11.6%
| 876.7%
| 2.3%
| €3.98K
|
| VIVO Cannabis Inc.
|
50
/ 100
| -0.19
| 17.1%
| -15.4%
| -106.6%
| -€193.27K
|
| Swedish Orphan Biovitrum AB (publ)
|
51
/ 100
| 7.6K
| 51.3%
| 24.6%
| 0.0%
| €648.99
|
